loading page

Response to Pegylated Interferon in a COVID-19 Positive Male with Metastatic Jejunal Neuroendocrine Tumor Treated with Everolimus
  • +1
  • Arthur Frankel,
  • Wai Yip,
  • Eknath Naik,
  • Hans Hasselbalch
Arthur Frankel
West Palm Beach VA Medical Center
Author Profile
Wai Yip
West Palm Beach VA Medical Center
Author Profile
Eknath Naik
West Palm Beach VA Medical Center
Author Profile
Hans Hasselbalch
Zealand University Hospital
Author Profile

Abstract

A 61 years old male had minimally symptomatic SARS-CoV-2 infection while taking everolimus. He remained RT-PCR positive for viral RNA for 52 days. Pegylated interferon for 4 weeks led to viral RNA clearance. The observations support consideration and further evaluation of combination therapy with everolimus plus interferon for COVID-19.

Peer review status:ACCEPTED

08 Feb 2021Submitted to Clinical Case Reports
09 Feb 2021Submission Checks Completed
09 Feb 2021Assigned to Editor
18 Feb 2021Reviewer(s) Assigned
29 Mar 2021Review(s) Completed, Editorial Evaluation Pending
31 Mar 2021Editorial Decision: Revise Minor
31 Mar 20211st Revision Received
01 Apr 2021Submission Checks Completed
01 Apr 2021Assigned to Editor
01 Apr 2021Review(s) Completed, Editorial Evaluation Pending
11 Apr 2021Editorial Decision: Accept